AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05378438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbe literacy Program in the form of workshop
Description: Two to Three hours of workshop on microbe literacy will be conducted as an intervention. Workshop includes discussion on various common microorganisms causing diseases, their sources, relationship with surroundings and management. Prime focus of the session will be on management via treatments and risk reduction via vaccination.
Study NCT05464303 — intervention group
Intervention type: DRUG
Intervention: Intravenous Antibodies
Description: Treatment is usually performed with sensitive third-generation cephalosporins, and medication is adjusted according to blood culture results
Study NCT05808959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education group
Description: After the discharge training given at the clinic in the postoperative period, the participants will be given structured training on sexual health.
Study NCT05382351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir group will receive entecavir orally once a day, 0.5mg each time, and fasting for 2h before and after taking the medicine
Study NCT05382351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir combined with Tenofovir Amibufenamide
Description: Entecavir combined with Tenofovir Amibufenamide group will be treated with entecavir and tenofovir amibufenamide. Entecavir is administered in the same way as before. enofovir amibufenamide orally 25mg once a day with meals
Study NCT06394713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLF31907
Description: intravenous administration, once every 3 weeks
Study NCT06394713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: intravenous administration, 125 mg/m2, d1 and d8, every 3 weeks
Study NCT06394713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous administration, 75mg/m2, d1, every 3 weeks
Study NCT04036708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wetting method (WTM)
Description: The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM were distributed to participating households. Women received this training bi-weekly for 12 months.
Study NCT04036708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wetting method (WTM)
Description: The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM were distributed to participating households. Women received this training bi-weekly for 12 months.
Study NCT04036708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC)
Description: The study team used MISC to train DRC mothers in practical day-to-day activities with their children to enhance 5 key mediational processes: 1) focusing (getting the child's attention and engaging directing them to learning experiences); 2) exciting (communicating excitement, appreciation, and affection with the learning experience); 3) expanding (making the child aware of how the learning experience transcends the present situation and can include past and future issues beyond the immediate need of the moment); 4) encouraging (emotional support to foster the child's sense of security and competence); and 5) regulating (helping to direct the child's behavior in constructive ways with a goal towards self-regulation).
Study NCT06548919 — intervention group
Intervention type: DRUG
Intervention: Endocrine therapy
Description: All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.
Study NCT06548919 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy Prednisone
Description: All chemotherapy treatment regimens approved for advanced breast cancer
Study NCT05957289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidimensional rehabilitation
Description: Multidimensional lifestyle interventions
Study NCT05931146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyNetDiary app group
Description: MyNetDiary will be used to track calories, and exercise while motivating for living a healthier life each day.The intervention period would last for three months. Total energy expenditure (TEE) of every participant enrolled into the study would be calculated at the start of the study and an exercise and diet plan with a calorie deficit of around 1000 kcal per week would be provided to the participant. The diet and exercise plan would be modified according to the new TEE of the participant. MyNetDiary app has built-in food and exercise activities with their respective calories' count. Moreover, customized foods and exercises can also be added into the application
Study NCT05931146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paper diary group
Description: Paper Diary will be used to track calories and exercise. The nutritional intake and exercise would be recorded for three months. The diet and exercise plans would be modified according to the new Total Energy Expenditure of the participants.
Study NCT04766021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Dose-response effect on thermogenesis
Study NCT04766021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control condition
Study NCT05718596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sweeps laser to use irrigation activation
Description: The SWEEPS fiber tip (25 µs ultra-short dual pulse mode-Auto SWEEPS mode) was inserted into the Er:YAG laser source (2,940 nm, 20 mJ per pulse, 15 Hz, 0.3 W power, and 50 µs pulse frequency). 3% NaOCl solution was activated in three periods of 20 s. Then, the same procedure was repeated with 2 ml of 17% EDTA solution.
Study NCT05718596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUI to use irrigation activation
Description: The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 3% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 2 mm behind the working length without touching the canal walls.
Study NCT05576896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Description: Prior to starting therapy, patients will have a pretreatment cross-sectional scan. Patients will then begin with encorafenib 300 mg daily starting with Cycle 1 day 1; then patients will receive IV cetuximab weekly, with 400 mg/m2 on C1D1 as a loading dose and 250 mg/m2 on all other days.~Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Study NCT05660720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and placebo (orelabrutinib tablet simulator)
Description: Orelabrutinib will be administered as 3 tablets (150mg) and placebo as 5 tablets (250mg)
Study NCT05660720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib will be administered as 8 tablets (400mg)
Study NCT05660720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (orelabrutinib tablet simulator)
Description: Placebo will be administered as 8 tablets (400mg).
Study NCT05660720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin hydrochloride
Description: Moxifloxacin hydrochloride will be administered as 1 tablet (400mg)
Study NCT06078943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: method comparison
Description: to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all ctBil and FHbF in heparinized arterial and venous neonatal whole blood in syringe measuring mode (S65, SP65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (C65)
Study NCT06078943 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: method comparison
Description: to quantify the relationship using comparison measurement from the same sample between ABL90 FLEX PLUS and the predicate device within the reportable range for all ctBil and FHbF in heparinized arterial and venous neonatal whole blood in syringe measuring mode (S65, SP65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (C65)
Study NCT06036472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard periodontal therapy (steps 1 & 2)
Description: participant will receive standard periodontal treatment consisting of two sessions of supra- and subgingival debridement (steps 1 and 2) under local anesthesia following current guidelines for periodontal therapy in patients with periodontitis (Herrera et al., 2022; Sanz et al., 2020). The use of chlorhexidine (0.12%) and cetylpyridinium chloride (0.05%) mouthwash will be prescribed twice a day for 15 days (Perio-Aid®, Dentaid, Barcelona, Spain). If needed, hopeless teeth might be extracted during this step.
Study NCT06036472 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: supragingival debridement with anesthesia (step 1)
Description: periodontal treatment consisting of two sessions of supragingival debridement with anesthesia (step 1) and administration of a placebo mouthwash (FluorAid®, Dentaid, Barcelona, Spain), twice a day for 15 days.
Study NCT06524518 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Chemotherapy combined with immunization
Description: MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy
Study NCT06524518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with immunization
Description: MRD positive patients receive chemotherapy ± immune for 4 cycles before adaptive therapy
Study NCT05213130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: A reminder to inform donors that their blood has saved patient's life in a questionnaire.
Study NCT05486273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interviews with coachs, semi-structured interviews and questionnaires
Description: You will be offered 6 coaching sessions at a rate of one session per month and the first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12. Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
Study NCT06495632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motrin and narcotic
Description: See described earlier
Study NCT06495632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motrin and narcotic
Description: See described earlier
Study NCT05486273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: semi-structured interviews and questionnaires
Description: The first interview will be conducted on the day of inclusion or within one month of inclusion, the others will take place at R6 and R12.Questionnaires will be administered on the day of inclusion and then at R1, R6, R9 and R12. RO is the day of inclusion and it corresponds to M3 (3 months post transplant)
Study NCT06179940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pairwise food selectivity protocol
Description: Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The experimental group will conduct the protocol activity in pairs.
Study NCT06179940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual food selectivity protocol
Description: Overall, the intervention aims to gradually expose the child to various foods, starting with familiarization, progressing to exposure without pressure, and finally, shaping positive behaviors using reinforcement and observing reactions to different food items. The control group will conduct the activity individually.
Study NCT05287451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Risk-Reducing Salpingo-Oophorectomy-RRSO
Description: complete questionnaires, standard-of-care laparoscopy to check the abdominal area before the assigned procedure
Study NCT05231070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeleSPC
Description: Multidisciplinary video consultations with the SPC team. The team is multiprofessional and composed by physician, nurse, psychologist, social worker, physiotherapist and a chaplain, which is in line with the staffing of most SPC teams in Denmark and abroad. Video consultations will follow the same approach already used in physical consultations at the Section of Palliative Medicine, considering patients' changing needs and providing differentiated treatment and support, with the addition of a psychological intervention for dyadic coping between patient and closest informal caregiver
Study NCT05450198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6194
Description: MK-6194 administered subcutaneously (SC)
Study NCT05450198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator to MK-6194 administered SC
Study NCT06403800 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05744999 — intervention group
Intervention type: PROCEDURE
Intervention: Coconut technique
Description: We recently developed a simple but effective laparoscopic technique to approach and ligate the cystic duct in cases of difficult acute cholecystitis. Three to four centimeters of the inflamed gallbladder wall was then cut using an electrocautery hook. An incision was made in a safe zone at the junction of the infundibulum and the body of the gallbladder. The separation between the outer layer and inner layer was searched. This clear identification of the confluence between the cystic duct and the body of the gallbladder represents the way to determine if the procedure was safely completed using the current technique. After successful identification, the cystic duct was clipped. The gallbladder can then be lifted and turned over, leaving the unidentified CBD untouched, and cholecystectomy can be carefully performed as usual. The inflamed posterior wall remained attached to the gallbladder bed of the liver.
Study NCT06156566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tecovirimat Oral Capsule
Description: 600 mg, twice daily, 14 days.
Study NCT06156566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules, twice daily, 14 days.
Study NCT06551805 — intervention group
Intervention type: DRUG
Intervention: Safety assessment of Ferumoxytol.
Description: Observe the injection site for skin invagination, rash, or urticaria during injection. Patients and their relatives were asked about any subjective adverse events before, during, and after drug injection, and all adverse events were recorded on the case report forms, and adverse events were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) from Grade 1 mild to Grade 5 death, Observe the vital signs of patients. Patients undergoing MRI underwent electrocardiogram (ECG) monitoring before and within 60 minutes after ferumoxytol administration, specifically including: biochemical panel, iron metabolism, liver and kidney function, cytokines, blood routine, urine routine, 24-hour urine volume, glycosylated hemoglobin and so on. All patients received a total of 3 blood and urine collections at 7 days before injection, 48 hours after injection, 1month to 3months after injection.
Study NCT06551805 — intervention group
Intervention type: DRUG
Intervention: Assessment of the diagnostic value of Ferumoxytol for MR angiography.
Description: steady-state, high-spatial-resolution, three-dimensional fast low-angle shot acquisition technique, T2W-MDIR imaging, polysaccharide superparamagnetic iron oxide injection enhanced T1W and T2W, T2\* mapping, and Steady state free precession sequence, T2 weighted black blood sequence, T2 preparation single shot steady state free precession sequence, T2\* weighted multi-echo/gradient echo sequence, polysaccharide superparamagnetic iron oxide injection enhanced imaging, Breath-triggered Transverse 3D Balance-Vortex Field Echo (b-TFE) Magnetic Resonance Angiography, iMSDE-SPGR Sequence, 4D Flow MRI. the MRI anxiety questionnaire.
Study NCT06036862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction
Description: Laparoscopic or open surgery was selected according to the patient's condition, surgical history and surgeon's experience.According to the extent of the rectal stenosis, the proximal colon was dissected.A circular incision was made above the dentate line and the broken end was sutured. After the intestinal cavity was closed, a single port was inserted through the anus, and a transanal endoscopic platform was established after pneumoperitoneum infusion.The stenotic and scar segments were removed free upward.Through the pelvic cavity and into the abdominal cavity from the bottom up. The narrow rectum and proximal colon were pulled out of the anus through the anus, and the diseased bowel was removed. According to the distance of the remaining distal rectum, stapler or manual anastomosis or Bacon operation was selected.
Study NCT05407896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myKIDNEY decision aid
Description: Patients and caregivers will be counselled using myKIDNEY decision aid which includes a video. Patients will be asked to complete a values clarification exercise (VCE). If a caregiver is recruited without their patient, he/she will be asked to complete the VCE on patient's behalf (i.e., surrogate). At the end of VCE, the participant will be given real-time feedback on which treatment might be the best fit for the patient. With the patient's consent, this information will be shared with the treating physician who can then make recommendations based on the patient's preferences.
Study NCT05001321 — intervention group
Intervention type: RADIATION
Intervention: The whole abdomen contrast-enhanced CT scan
Description: All the participants were measured by the whole abdomen contrast-enhanced CT scan.
Study NCT05001321 — intervention group
Intervention type: OTHER
Intervention: H&E stained sections and slides
Description: HE pathological examination was performed on all specimens of enrolled patients.
Study NCT05374252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
Study NCT05374252 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemoradiotherapy
Description: Two cycles of concurrent mytomicin C and 5-fluorouracil combined with IMRT
Study NCT04233190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
Description: one inhalation, twice daily
Study NCT04233190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
Description: one inhalation, twice daily
Study NCT05839054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality audio and visual glass (Roller Coasters, group 1)
Description: During the inhaler treatment, the child was shown Roller Coasters with VR glasses.
Study NCT05839054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality audio and visual glass (Wild Dolphins, group 2)
Description: During the inhaler treatment, the child was shown Wild Dolphins with VR glasses.
Study NCT05138809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Use online exercise platform
Study NCT06500143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric ultrasound
Description: Using a curved array low-frequency abdominal probe (2-5 MHz) with abdominal presets and with the patient in right lateral decubitus position, the gastric antrum will be identified in a standardized plane at the level of the aorta. The stomach will be considered empty if the antrum appears flat or round with anterior and posterior walls collapsed. Normal gastric secretions and clear fluids have an anechoic or hypoechoic aspect on ultrasonography. Solid or thick fluids have a hyperechoic aspect and can create ring-down artifacts blurring gastric content, its posterior wall, the pancreas and the aorta. Following qualitative examination, quantitative assessment will be performed if there is presence of clear fluids. The cross-sectional area (CSA) of the antrum will be measured with three measurements to calculate a mean value.
Study NCT04934137 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensoria
Description: The Sensoria system uses a force-sensing mat installed under the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays information about weight shifts, goal-setting functions, and feedback on performance/outcomes.
Study NCT04934137 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AW-Shift
Description: The AW-Shift system uses a pressure-sensing mat installed on top of the wheelchair cushion that connects via Bluetooth to a mobile app. The mobile app displays visual representation of the seating surface and can set reminders for weight shifts.
Study NCT05261022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Love Together, Parent Together (L2P2)
Description: Love Together Parent Together (L2P2) is a brief, low-intensity relationship intervention intended to improve the interparental relationship for parents of young children.